Neurocrine Biosciences Inc To Host R&D Day Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Brian Skorney - Robert W. Baird & Co Inc - Analyst : Thanks, Brian Abrahams, RBC, thanks for the really helpful presentation. Two questions on Oaf Amator, one for Doctor Crystal and one for the company. I guess for Doctor Crystal, you kind of alluded to this. If you look at the Madras curves, in the study, there's a sharp decline through, day 28, and then, the higher dose, levels out, whereas the 1 meg continues improving, so. I'm curious if there's any mechanistic explanation for this, and is there any risk you might foresee of tachyphylaxis with your longer dosing or higher exposures. And then for the company, I'm curious if you give us some sense of how far along the Phase 3 studies are at this point in terms of enrollment, just kind of broadly speaking. And the types of safety and erm analysis that are built in, I guess I'm sort of wondering when in the course of the pivotal studies, are you going to be comfortable that, an eleptogenic signal is unlikely to ultimately crop up. Thanks.